MTOR and neoplasm: In line with this, based on clinical trials and pre-clinical data, the therapeutic target of the PI3K/AKT/mTOR signaling pathway dose not merely attenuates tumor malignancy and metastasis, but also enhances the tumor immunosurveillance and anti-tumor immunity properties 29.